CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com
About Us
Overview
Our work in Biosimilars
Board of Directors
Executive Leadership Team
Our Stories
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Our Business
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Our Products
Global
India
Partners
Global Footprint
Our Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Investors
Newsroom
Press Releases
Company Statements
Our Stories
Media Contacts
Careers
Working With Us
Now Hiring
Contact Us
Company Statements 2019
Biocon Biologics
/
News – Posts
/
Company Statements
/
Company Statements 2019
U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru
Fri, 20-Sep-2019
Posted by: Biocon Biologics
No Comments
U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged
Sat, 31-Aug-2019
Posted by: Biocon Biologics
No Comments
U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru
Sat, 31-Aug-2019
Posted by: Biocon Biologics
No Comments
Pre-Approval U.S. FDA Inspection Conducted at Biocon’s Insulins Facilities in Malaysia
Mon, 08-Jul-2019
Posted by: Biocon Biologics
No Comments
Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification
Fri, 14-Jun-2019
Posted by: Biocon Biologics
No Comments
Biocon Facility Completes Pre Approval U.S. FDA Inspection
Wed, 06-Mar-2019
Posted by: Biocon Biologics
No Comments
